Last reviewed · How we verify
NCT05931042
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
trial testing Trastuzumab in HER2+ Breast Cancer in 1,209 participants. Completed in 18 June 2023.
15 June 2023
Quick facts
| Lead sponsor | Rawalpindi Medical College |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,209 |
| Start date | 1 June 2023 |
| Primary completion | 15 June 2023 |
| Estimated completion | 18 June 2023 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Trastuzumab (trastuzumab) — full drug profile →
Conditions studied
- HER2+ Breast Cancer — all drugs for HER2+ Breast Cancer →
Sponsor
Rawalpindi Medical College
Who can join
18 and older, female only, with HER2+ Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this systematic review is to assess the effectiveness of neoadjuvant chemotherapy and Trastuzumab in achieving pathological complete response (pCR) in patients with HER2-positive breast cancer. The main questions it aims to answer are: * What is the overall rate of pathological complete response (pCR) in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and Trastuzumab? * Are there any variations in the definition of pCR among the included trials? Participants in the selected clinical trials were HER2-positive breast cancer patients with non-metastatic operable, locally advanced, or inflammatory breast cancer. The main tasks participants were asked to do and the treatments they received are as follows: * Undergo neoadjuvant chemotherapy: Participants received chemotherapy treatment before their primary surgery. * Receive Trastuzumab: Participants were administered Trastuzumab, a targeted therapy for HER2-positive breast cancer. Researchers would compare the group of participants receiving neoadjuvant chemotherapy and Trastuzumab to other groups, if present, to see if there are differences in the rates of pathological complete response (pCR) or other effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05931042
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Trastuzumab
Trials testing the same drug.
- NCT07413939 — RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastati · Phase 2, PHASE3 · not yet recruiting
- NCT07441460 — A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer · Phase 3 · recruiting
- NCT07402473 — EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer · Phase 2 · not yet recruiting
- NCT07377643 — IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer · Phase 3 · recruiting
- NCT07366840 — RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for HER2+ Breast Cancer
Currently open trials in the same condition.
- NCT06844669 — HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy · Phase 2 · active not recruiting
- NCT05534438 — A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Appr · Phase 2 · recruiting
- NCT04585750 — The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · Phase 1, PHASE2 · recruiting
Other Rawalpindi Medical College trials
Trials by the same sponsor.
- NCT07420127 — Comparison of Two Different Doses of Phenylephrine on Oxytocin Hemodynamic Effect · Phase 4 · recruiting
- NCT07409688 — Pain Relief Following Laparoscopic Cholecystectomy While Comparing Intra Abdominal Versus Sub Cutaneous Local Anesthetic · Phase 4 · recruiting
- NCT07088146 — Dexamethasone in Prolonging the Duration of Spinal Anesthesia Among Pregnant Patients · Phase 4 · recruiting
- NCT07092943 — Driving Pressure Guided Mechanical Ventilation Versus Lung Protective Ventilation Among Patients Undergoing Elective Sur · NA · recruiting
- NCT07078786 — Effect of Pre-delivery Dexamethasone in Comparison With Betamethasone on Fetal Heart Trace · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05931042 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rawalpindi Medical College
- Last refreshed: 5 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05931042.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing